News & Views | Published:

IMMUNOTHERAPY

Modeling cytokine release syndrome

Complete leukemic responses to chimeric antigen receptor–modified T cells are invariably accompanied by severe toxicity. Recently developed animal models allow mechanistic dissection and prevention of toxicity without loss of therapeutic benefit.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Schmiegelow, K. et al. Lancet Oncol. 17, e231–e239 (2016).

  2. 2.

    Porter, D., Frey, N., Wood, P. A., Weng, Y. & Grupp, S. A. J. Hematol. Oncol. 11, 35 (2018).

  3. 3.

    Turtle, C. J. et al. Sci. Transl. Med. 8, 355ra116 (2016).

  4. 4.

    Gust, J. et al. Cancer Discov. 7, 1404–1419 (2017).

  5. 5.

    Morgan, R. A. Mol. Ther. 20, 882–884 (2012).

  6. 6.

    Norelli, M., et al. Nat. Med. https://doi.org/10.1038/s41591-018-0036-4 (2018).

  7. 7.

    Giavridis, T., et al. Nat. Med. https://doi.org/10.1038/s41591-018-0041-7 (2018).

  8. 8.

    Bedoya, F., Frigault, M. J. & Maus, M. V. Mol. Ther. 25, 314–320 (2017).

  9. 9.

    Shultz, L. D. et al. J. Immunol. 154, 180–191 (1995).

  10. 10.

    Hay, K. A. et al. Blood 130, 2295–2306 (2017).

  11. 11.

    Shum, T. et al. Cancer Discov. 7, 1238–1247 (2017).

  12. 12.

    Cruz, C. R. et al. Cytotherapy 12, 743–749 (2010).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Cliona Rooney.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1: Modeling CRS after CAR T cell transfer in mice reveals macrophages to be key players in the development of CRS and neurotoxicity.